These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 12001650)

  • 1. Botulinum toxin for treatment of parkinsonian sialorrhea.
    Friedman A; Potulska A
    Neurol Neurochir Pol; 2001; 35 Suppl 3():23-7. PubMed ID: 12001650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of severe drooling with botulinum toxin in amyotrophic lateral sclerosis and Parkinson's disease: efficacy and possible mechanisms.
    Møller E; Karlsborg M; Bardow A; Lykkeaa J; Nissen FH; Bakke M
    Acta Odontol Scand; 2011 May; 69(3):151-7. PubMed ID: 21198339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin.
    Friedman A; Potulska A
    Parkinsonism Relat Disord; 2001 Oct; 7(4):329-332. PubMed ID: 11344019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism.
    Mancini F; Zangaglia R; Cristina S; Sommaruga MG; Martignoni E; Nappi G; Pacchetti C
    Mov Disord; 2003 Jun; 18(6):685-8. PubMed ID: 12784273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin A as treatment for drooling saliva in PD.
    Pal PK; Calne DB; Calne S; Tsui JK
    Neurology; 2000 Jan; 54(1):244-7. PubMed ID: 10636161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saliva changes in Parkinson's disease patients after injection of Botulinum neurotoxin type A.
    Tiigimäe-Saar J; Tamme T; Rosenthal M; Kadastik-Eerme L; Taba P
    Neurol Sci; 2018 May; 39(5):871-877. PubMed ID: 29460161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
    Lagalla G; Millevolte M; Capecci M; Provinciali L; Ceravolo MG
    Mov Disord; 2006 May; 21(5):704-7. PubMed ID: 16440332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease.
    Ondo WG; Hunter C; Moore W
    Neurology; 2004 Jan; 62(1):37-40. PubMed ID: 14718694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease.
    Dogu O; Apaydin D; Sevim S; Talas DU; Aral M
    Clin Neurol Neurosurg; 2004 Mar; 106(2):93-6. PubMed ID: 15003297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin injections for children with excessive drooling.
    Hassin-Baer S; Scheuer E; Buchman AS; Jacobson I; Ben-Zeev B
    J Child Neurol; 2005 Feb; 20(2):120-3. PubMed ID: 15794177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin to reduce saliva flow: selected indications for ultrasound-guided toxin application into salivary glands.
    Ellies M; Laskawi R; Rohrbach-Volland S; Arglebe C; Beuche W
    Laryngoscope; 2002 Jan; 112(1):82-6. PubMed ID: 11802043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of botulinum toxin A for treatment of drooling.
    Lipp A; Trottenberg T; Schink T; Kupsch A; Arnold G
    Neurology; 2003 Nov; 61(9):1279-81. PubMed ID: 14610139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin in the treatment of sialorrhea.
    Svetel M; Vasić M; Dragasević N; Pekmezović T; Petrović I; Kostić V
    Vojnosanit Pregl; 2009 Jan; 66(1):9-12. PubMed ID: 19195257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin B reduces sialorrhea in parkinsonism.
    Racette BA; Good L; Sagitto S; Perlmutter JS
    Mov Disord; 2003 Sep; 18(9):1059-61. PubMed ID: 14502678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does botulinum toxin decrease frequency and severity of sialorrhea in Parkinson's disease?
    Nóbrega AC; Rodrigues B; Torres AC; Enzo A; Melo A
    J Neurol Sci; 2007 Feb; 253(1-2):85-7. PubMed ID: 17229441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors in the Efficacy, Safety, and Impact on Quality of Life for Treatment of Drooling with Botulinum Toxin Type A in Patients with Cerebral Palsy.
    Gonzalez-L MD; Martinez C; Bori Y Fortuny I; Suso-Vergara S
    Am J Phys Med Rehabil; 2017 Feb; 96(2):68-76. PubMed ID: 28099276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin type A and type B for sialorrhoea in Parkinson's disease: a case for switching therapy?
    Santamato A; Panza F; Solfrizzi V; Frisardi V; Ranieri M; Fiore P
    J Rehabil Med; 2008 Nov; 40(10):882-3. PubMed ID: 19242630
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial.
    Chinnapongse R; Gullo K; Nemeth P; Zhang Y; Griggs L
    Mov Disord; 2012 Feb; 27(2):219-26. PubMed ID: 21887710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies.
    Ellies M; Laskawi R; Rohrbach-Volland S; Arglebe C
    J Oral Maxillofac Surg; 2003 Apr; 61(4):454-7. PubMed ID: 12684962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical management of chronic sialorrhea in pediatric patients: 10-year experience from one tertiary care institution.
    Formeister EJ; Dahl JP; Rose AS
    Int J Pediatr Otorhinolaryngol; 2014 Aug; 78(8):1387-92. PubMed ID: 24974144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.